A Single-Arm, Multicenter, Open-Label, Phase 2 Study of Nab-Paclitaxel (Abraxane) and Carboplatin Chemotherapy Plus Necitumumab (LY3012211) in the First-Line Treatment of Patients With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC)

Trial Profile

A Single-Arm, Multicenter, Open-Label, Phase 2 Study of Nab-Paclitaxel (Abraxane) and Carboplatin Chemotherapy Plus Necitumumab (LY3012211) in the First-Line Treatment of Patients With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 06 Oct 2017

At a glance

  • Drugs Necitumumab (Primary) ; Carboplatin; Paclitaxel
  • Indications Non-small cell lung cancer; Squamous cell cancer
  • Focus Therapeutic Use
  • Sponsors Eli Lilly
  • Most Recent Events

    • 08 Mar 2017 Planned End Date changed from 1 Feb 2018 to 1 Jun 2018.
    • 08 Mar 2017 Planned primary completion date changed from 1 Oct 2017 to 1 Feb 2018.
    • 11 Oct 2016 Trial design was presented at the 41st European Society for Medical Oncology Congress
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top